AU2012340446B2 - Apoaequorin for reducing neuronal injury due to ischemia - Google Patents

Apoaequorin for reducing neuronal injury due to ischemia Download PDF

Info

Publication number
AU2012340446B2
AU2012340446B2 AU2012340446A AU2012340446A AU2012340446B2 AU 2012340446 B2 AU2012340446 B2 AU 2012340446B2 AU 2012340446 A AU2012340446 A AU 2012340446A AU 2012340446 A AU2012340446 A AU 2012340446A AU 2012340446 B2 AU2012340446 B2 AU 2012340446B2
Authority
AU
Australia
Prior art keywords
apoaequorin
subject
neurons
brain ischemia
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012340446A
Other languages
English (en)
Other versions
AU2012340446A1 (en
Inventor
James R. Moyer
Mark Y. Underwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stillwaters Bioscience Group LLC
Original Assignee
Stillwaters Bioscience Group LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stillwaters Bioscience Group LLC filed Critical Stillwaters Bioscience Group LLC
Publication of AU2012340446A1 publication Critical patent/AU2012340446A1/en
Application granted granted Critical
Publication of AU2012340446B2 publication Critical patent/AU2012340446B2/en
Assigned to STILLWATERS BIOSCIENCE GROUP, LLC reassignment STILLWATERS BIOSCIENCE GROUP, LLC Request for Assignment Assignors: QUINCY BIOSCIENCE, LLC
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2012340446A 2011-11-15 2012-11-15 Apoaequorin for reducing neuronal injury due to ischemia Active AU2012340446B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161559816P 2011-11-15 2011-11-15
US61/559,816 2011-11-15
PCT/US2012/065291 WO2013074798A1 (en) 2011-11-15 2012-11-15 Apoaequorin for reducing neuronal injury due to ischemia

Publications (2)

Publication Number Publication Date
AU2012340446A1 AU2012340446A1 (en) 2014-05-29
AU2012340446B2 true AU2012340446B2 (en) 2017-08-31

Family

ID=47295186

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012340446A Active AU2012340446B2 (en) 2011-11-15 2012-11-15 Apoaequorin for reducing neuronal injury due to ischemia

Country Status (23)

Country Link
US (1) US20140294874A1 (enExample)
EP (1) EP2780027B1 (enExample)
JP (1) JP6181061B2 (enExample)
KR (1) KR102009932B1 (enExample)
CN (1) CN104244966B (enExample)
AU (1) AU2012340446B2 (enExample)
BR (1) BR112014011630A2 (enExample)
CA (1) CA2855719C (enExample)
CY (1) CY1119300T1 (enExample)
DK (1) DK2780027T3 (enExample)
ES (1) ES2643392T3 (enExample)
HR (1) HRP20171532T1 (enExample)
HU (1) HUE035017T2 (enExample)
IL (1) IL232494B (enExample)
IN (1) IN2014CN04009A (enExample)
LT (1) LT2780027T (enExample)
MX (1) MX350259B (enExample)
PL (1) PL2780027T3 (enExample)
PT (1) PT2780027T (enExample)
SG (1) SG11201402364WA (enExample)
SI (1) SI2780027T1 (enExample)
WO (1) WO2013074798A1 (enExample)
ZA (1) ZA201403577B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40959A (fr) 2014-11-11 2017-09-19 Quincy Bioscience Llc Compositions contenant de l'apoaéquorine et leurs procédés d'utilisation pour traiter l'inflammation neuronale
KR20180001229A (ko) 2016-06-27 2018-01-04 삼성에스디아이 주식회사 이차 전지의 제조 방법 및 이를 이용한 이차 전지
JP2019532936A (ja) * 2016-09-23 2019-11-14 クインシー バイオサイエンス，リミティド ライアビリティ カンパニー アポエクオリンおよびビタミンｄ含有組成物およびそれらの使用方法
RU2642961C1 (ru) * 2017-02-21 2018-01-29 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики ишемии головного мозга

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114597A1 (en) * 2008-03-11 2009-09-17 Quincy Bioscience, Llc Apoaequorin-containing compositions and methods of using same
US7671015B2 (en) * 2004-06-21 2010-03-02 Quincy Bioscience, Llc Aequorin-containing compositions and methods of using same
US20110130336A1 (en) * 2009-10-16 2011-06-02 Quincy Bioscience, Llc Method of treating ischemic injury using apoaequorin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0602992D0 (en) * 2006-02-15 2006-03-29 Morvus Technology Ltd Methods, genes and proteins
JP5919604B2 (ja) * 2008-08-08 2016-05-18 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 抗膵癌抗体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671015B2 (en) * 2004-06-21 2010-03-02 Quincy Bioscience, Llc Aequorin-containing compositions and methods of using same
WO2009114597A1 (en) * 2008-03-11 2009-09-17 Quincy Bioscience, Llc Apoaequorin-containing compositions and methods of using same
US20110130336A1 (en) * 2009-10-16 2011-06-02 Quincy Bioscience, Llc Method of treating ischemic injury using apoaequorin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DETERT J.A. et al., Society for Neuroscience Abstract Viewer and Itinerary Planner, 39th Annual Meeting of the Society For Neuorscience, 2009 *

Also Published As

Publication number Publication date
KR102009932B1 (ko) 2019-08-12
BR112014011630A2 (pt) 2017-06-27
CA2855719A1 (en) 2013-05-23
AU2012340446A1 (en) 2014-05-29
US20140294874A1 (en) 2014-10-02
IL232494A0 (en) 2014-06-30
JP2014533692A (ja) 2014-12-15
HRP20171532T1 (hr) 2017-11-17
WO2013074798A1 (en) 2013-05-23
IN2014CN04009A (enExample) 2015-10-23
PL2780027T3 (pl) 2017-11-30
CY1119300T1 (el) 2018-02-14
ES2643392T3 (es) 2017-11-22
KR20140097369A (ko) 2014-08-06
SG11201402364WA (en) 2014-09-26
MX350259B (es) 2017-08-31
NZ624736A (en) 2016-05-27
CA2855719C (en) 2021-10-26
IL232494B (en) 2019-03-31
EP2780027B1 (en) 2017-07-19
CN104244966B (zh) 2019-01-11
PT2780027T (pt) 2017-10-04
ZA201403577B (en) 2015-07-29
EP2780027A1 (en) 2014-09-24
MX2014005798A (es) 2014-05-30
HUE035017T2 (en) 2018-03-28
CN104244966A (zh) 2014-12-24
HK1202417A1 (en) 2015-10-02
JP6181061B2 (ja) 2017-08-16
LT2780027T (lt) 2017-10-25
SI2780027T1 (sl) 2017-11-30
DK2780027T3 (en) 2017-09-25

Similar Documents

Publication Publication Date Title
AU672606B2 (en) Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
Hartung Anti-inflammatory effects of granulocyte colony-stimulating factor
Smith et al. Granulocyte colony-stimulating factor versus placebo in addition to penicillin G in a randomized blinded study of gram-negative pneumonia sepsis: analysis of survival and multisystem organ failure
AU2012340446B2 (en) Apoaequorin for reducing neuronal injury due to ischemia
CA2520515C (en) S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment
US20170173110A1 (en) Combination therapy for ameliorating adverse side effects caused by chemotherapy
CA3031083A1 (en) Uses of il-12 as a replacement immunotherapeutic
EP2424527A1 (en) Mast cell stabilizers to prevent or treat laminitis
HK1202417B (en) Apoaequorin for reducing neuronal injury due to ischemia
NZ624736B2 (en) Apoaequorin for reducing neuronal injury due to ischemia
EP1100463B1 (en) New injectable formulations containing ramoplanin
AU2008219269B2 (en) Combination therapy using TNF and alfa-galactosyl ceramide
KR20170072350A (ko) 아포에쿼린-함유 조성물 및 이의 뉴런 염증을 치료하기 위한 사용 방법
JP4629964B2 (ja) ウシの消化器疾患治療剤
KR20200071338A (ko) Ｎｋ 세포 활성 조절을 통한 비만의 예방 또는 치료 방법
JPWO2007074727A1 (ja) 口腔カンジダ症治療剤
JP2011063522A (ja) 活性安定化製剤
Quinton et al. Use of colony-stimulating factors for treatment of neutropenia and infectious diseases
JPWO2007037099A1 (ja) 乳房炎の治療剤
JP2010189448A (ja) ウシの消化器疾患治療剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: STILLWATERS BIOSCIENCE GROUP, LLC

Free format text: FORMER OWNER(S): QUINCY BIOSCIENCE, LLC